読み込み中
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.
前日終値
$29.88
+$0.15 · +0.50%
時間外
$29.88
$0.00 · 0.00%
10月9日 19:30 ET
日中の時刻はETです。市場データは遅延する場合があります。
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.
日中レンジ
現在 $29.88
52週レンジ
現在 $29.88
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
33
割高
センチメント
53
まちまち
リスク
50
やや高いリスク
モメンタム
73
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.
日中レンジ
現在 $29.88
52週レンジ
現在 $29.88
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上原価 | — | — | — | −84.6万 USD | — |
| 粗利益 | — | — | — | 84.6万 USD | — |
| 研究開発 | 2.15億 USD | 1.26億 USD | 7822.5万 USD | 6983.9万 USD | 2248.4万 USD |
| 販売・一般管理 | 1億 USD | 4099.8万 USD | 2378.7万 USD | 2191万 USD | 1191.8万 USD |
| 営業費用 | 3.15億 USD | 1.67億 USD | 1.02億 USD | 9174.9万 USD | 3440.2万 USD |
| 受取利息 | 2447.9万 USD | 2071.4万 USD | 797.9万 USD | 175万 USD | 1.5万 USD |
| 支払利息 | 753.1万 USD | 762.6万 USD | 378.6万 USD | 99.2万 USD | 2万 USD |
| 減価償却費と償却費 | 46.8万 USD | 10.5万 USD | 2.1万 USD | −84.6万 USD | 17.6万 USD |
| 営業利益 | −3.15億 USD | −1.67億 USD | −1.02億 USD | −9090.3万 USD | −3440.2万 USD |
| 純利益 | −3億 USD | −1.52億 USD | −9599万 USD | −8905.6万 USD | −3260.9万 USD |
会社概要が更新されました 2026年10月10日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI6610.85万0.00%2.3兆 USD0.03%$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI5658.31万0.56%98.74億 USD0.35%$153.77+3.00%
iShares Russell 2000 ETFIWM5002.13万0.06%782.66億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF2615.15万0.03%954億 USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO1754.77万0.13%139.72億 USD0.24%$356.78+0.94%
iShares Biotechnology ETFIBB1347.09万0.13%102.79億 USD0.44%$206.49+3.00%
Vanguard Russell 2000 ETFVTWO1251.56万0.07%180億 USD0.06%$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA975.52万0.04%217.28億 USD0.03%$32.79+0.40%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
